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In the face of growing controversy about the utility of genetic mouse models of human disease,
Rothwell et al. report on a shared mechanism by which two different neuroligin-3 mutations,
associated with autism spectrum disorders in humans, produce an enhancement in motor learning.
The open question is how much we can learn about human ills from such models.Progress in basic biological research is
much beholden to the use of genetically
engineered mice. Such animals have
made it possible to study functions of
many genes and to investigate diverse
biological processes in a deeply charac-
terized vertebrate model. Many transla-
tional biologists have also cast their lot
with genetically manipulated mice, at-
tempting to model human disease and
often to predict efficacy of new therapeu-
tic agents. In contrast to their use in basic
science, however, recent years have
seen growing disillusionment with murine
models of human disease, especially
their longstanding use in drug discovery
efforts. Questions have multiplied con-
cerning the value even of genetic mouse
models constructed with highly penetrant
alleles that cause human disease
because of the large number of com-
pounds that ‘‘cure’’ mouse models only
to fail in human trials (Seok et al., 2013).
Some such failures reflect inadequate
methodology. Critics have cited such
issues as failures to confirm the precise
mutations introduced into the mouse
genome; inattention to the effects of the
genetic backgrounds of the mouse lines
being studied; problems in the breeding
and care of mice that introduce stress
or infection; inadequate powering of
studies; and introduction of bias in the
analysis of phenotypes (Ioannidis, 2012;
Perrin, 2014). Many such methodological
issues should prove to be addressable
by the scientific community, although
the cost and difficulty should not be
underestimated. There are, however,
deeper scientific issues to be concerned
with. The impressive paper by Rothwell
et al. (2014) in this issue of Cell makes a
concerted effort to meet such challengesin the use of genetically engineered mice
to investigate the function of penetrant
human disease-associated alleles. Two
such challenge seem particularly deserv-
ing of comment: (1) the complex relation-
ship of genotypes to phenotypes even for
highly penetrant mutations implicated in a
single human disease and (2) attention to
evolutionary conservation. For studies of
the nervous system, this generally re-
quires the selection of neural phenotypes
that involve cells, synapses, and circuits
that are plausibly conserved in evolution
and thus potentially relevant to the human
condition. Given the circumspection of
Rothwell et al. (2014) in their claims for
the validity of their mouse lines asmodels,
and given their meticulous investigation of
phenotype, it is worth asking how far they
have gotten and how far mice can carry us
in the investigation of autism spectrum
disorder (ASD)-like human phenotypes.
Highly penetrant mutations in the gene
encoding neuroligin-3 (NLGN3 or NL3)
are associated with ASDs in humans and
produce robust behavioral phenotypes
in transgenic mice. Neuroligin-3, a post-
synaptic cell-adhesion molecule, is a
member of a family of proteins that com-
plex with neurexins, together affecting
synapse formation and regulating synap-
tic properties and function. Rothwell
et al. (2014) compare an NL3 knockout
mouse with a knockin mouse bearing
the R451C point mutation that causes
an Arg to Cys substitution. This mutation
produces a protein that is not efficiently
trafficked in the cell, resulting in an
approximately 90% reduction in protein
levels. Although both of these mutations
cause ASDs in humans, they had pre-
viously been shown to produce markedly
different behavioral phenotypes whenCintroduced into mice (Etherton et al.,
2011).
Rothwell et al. (2014) thus set out to
identify a shared behavioral phenotype
in these two different NL3 mutant mice
and then to examine its synaptic basis.
They find that both mouse lines exhibit
enhanced motor learning on an acceler-
ating rotating rod (rotarod) task. The
authors suggest that the observed
enhancement of motor learning might
model the repetitive behaviors that are
a core characteristic of ASDs. Their
thorough investigation of synaptic mech-
anisms reveals that the mechanism of
enhanced motor learning is impairment
of synaptic inhibition onto D1-dopamine
receptor-expressing medium spiny neu-
rons (D1-MSNs), which would alter the
balance between excitation and inhibi-
tion. The authors support their central
findings with conditional knockouts to
examine and rule out a role for alternative
brain regions and cell types. Once the
evidence focuses their investigation on
MSNs, the major output neurons of the
dorsal and ventral striatum, they measure
mRNA levels in the four major MSN
classes, those expressing D1 versus D2
dopamine receptors and those found in
dorsal versus ventral striatum.
The MSNs responsible for enhanced
motor learning express D1 receptors.
Somewhat surprisingly, however, the
relevant D1-MSNs are not in the dorsal
striatum, which has often been reported
to play a central role in motor learning,
but rather in the ventral striatum, specif-
ically the nucleus accumbens (NAc),
which is involved in reward-related
learning and reinforcement. In retrospect,
the role of the NAc in learning the rotarod
task could be understood, at least partly,ell 158, July 3, 2014 ª2014 Elsevier Inc. 13
in light of another example of learning: the
transition from the voluntary consumption
of rewarding drugs to the compulsive
drug use that characterizes addiction.
The ventral striatum plays a critical role
in the early stages of learning and con-
solidating drug-taking behaviors, but
control transitions to the dorsal striatum
as drug-taking becomes habitual (Everitt
and Robbins, 2005).
ASDs are a genetically and clinically
heterogeneous group of neurodevelop-
mental disorders that manifest in the early
years of life and are characterized by
abnormalities in social communication
and interaction and by repetitive patterns
of behavior and restricted interests. This
core syndrome may be accompanied
by intellectual disability and other symp-
toms. ASDs are highly genetically influ-
enced, with a small percentage caused
by damaging mutations to protein-coding
genes (such as NL3) and another small
fraction influenced by copy-number varia-
tions (CNVs) of genomic segments. Se-
vere mutations in single genes and large
CNVs can either be inherited or can occur
de novo. In addition to NL3, ASDs have
been associated with deleterious muta-
tions in other genes that encode synaptic
proteins including NLGN4X, NRXN1,
SHANK2, and SHANK3.
Rothwell et al. (2014) find that the
phenotype shared by their two mutant
mouse lines is a behavioral gain-of-func-
tion, enhanced motor learning. In contrast
to this gain of function, interpretation of
the significance of cognitive or behavioral
deficit phenotypes in ASD models faces
significant confounding issues. Delete-
rious mutations in genes associated with
monogenic (or nearly monogenic) forms
of autism as well as CNVs associated
with autism or schizophrenia cause
generalized intellectual disability as well
as psychiatric symptoms. Indeed, the
intellectual disability phenotype is more
highly penetrant than symptoms of autism
or schizophrenia. In such cases, it can be
treacherous to assign a cognitive deficit
phenotype produced in a genetic mouse
model to autism or schizophrenia, as
opposed to intellectual disability.
Returning to the broader issues con-
cerning use of genetic mouse models,
Rothwell et al. (2014) have made signifi-
cant contributions to basic neuroscience.14 Cell 158, July 3, 2014 ª2014 Elsevier Inc.They have provided new understanding of
neuroligin-3 function and exciting new
ideas about motor learning. This study
has therefore advanced scientific knowl-
edge whether or not enhanced rotarod
learning can be usefully employed as a
disease model or as a phenotypic screen
for new therapies.
The divergent phenotypes previously
reported of the NL3 knockout and the
R451C point mutation (Etherton et al.,
2011), and the 90 million years of evolu-
tionary separation since humans and ro-
dents shared a common ancestor, make
it implausible that either neuroligin-3
mouse mutant could serve as a complete
or general ASD model. A more sensible
query is whether the motor-learning
phenotype and its synaptic mecha-
nism—impaired synaptic inhibition onto
D1-MSNs in the NAc—can model some
narrower aspect of ASDs. Favoring the
possibility for more focused translational
utility is the fact that the NL3 mutations
examined are highly penetrant in both
humans and the mouse strains used.
(Given that most ASDs, schizophrenia,
and the other psychiatric disorders that
have been examined have a significant
polygenic component of risk based on
very large numbers of low-penetrance
alleles, a significant unsolved challenge
awaits those attempting to create the
next generation of animal models [McCar-
roll and Hyman 2013].) Also important
is what appears to be a reasonable level
of similarity, perhaps attributable to
evolutionary conservation, of striatal cell
types, their major neurotransmitters and
receptors, and important aspects of their
physiology (Gerfen and Surmeier, 2011).
Such cannot be said of human versus
rodent cerebral cortex.
Many readers might wonder how
rotarod learning can possibly model the
repetitive behaviors of human ASDs. Of
course, there are many biological steps
between genes and behavioral outputs;
moreover, the social and environmental
contexts that shaped human behavior
compared with that of rodents have
been highly divergent over the course
of evolutionary time. Thus, behaviors
resulting from mutations introduced
into the mouse genome might best be
construed as no more than potentially
useful readouts of underlying neural pro-cesses. What matters in judging the NL3
mutant mice as potential disease models
is whether neuroligin-3 function and neu-
ral adaptations to low levels of the protein
have been adequately preserved in evolu-
tion between the chosen animal model,
here the mouse, and humans. What
matters for predicting the efficacy of
therapies can be thought of similarly.
Drugs act on molecular targets, not
directly on behaviors or other symptoms.
Thus, predictive validity for therapies
requires good conservation of the mole-
cular mechanism by which activation or
inhibition of a molecular target affects
a well-chosen readout that correlates
strongly with a human symptom. Could
rotarod learning be used to screen for
effective therapies for a subset of symp-
toms of human ASDs? There is not
enough information to answer that ques-
tion, but Rothwell et al. (2014) are
following a promising path. It is long past
the time when translational neuroscience
should have stopped asking to what
degree an animal behavior is reminiscent
of a human symptom to focus instead on
molecular and cellular mechanisms. In
that case, the careful and selective use
of mouse models produced with pene-
trant human genesmay carry translational
scientists farther toward therapies.REFERENCES
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